Amneal Pharmaceuticals AMRX Estimates

NASDAQ AMRX
$17.30 +0.25 (+1.48%)
As of: Sep 9, 2026 · 12:04 PM EDT
Analyst Estimates

Amneal Pharmaceuticals, Inc. Revenue Estimates

Periods 22
Next Period Q3 26
Consensus 781.96 M

Analysts expect Amneal Pharmaceuticals, Inc. to report revenue of 781.96 M for Q3 26, against a range of 731.82 M to 832.11 M. The most recent reported quarter, Q2 26, came in at 796.20 M, a 2.3% miss against the 815.10 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 702.47 M730.52 M695.42 M724.51 M784.51 M814.32 M722.52 M796.20 M--------
High Estimate 764.15 M771.05 M748.93 M740.55 M780.09 M807.79 M710.18 M876.78 M832.11 M910.02 M876.04 M853.23 M885.92 M991.69 M881.67 M1.00 B
Low Estimate 701.16 M725.76 M626.76 M670.00 M728.83 M723.73 M659.86 M753.42 M731.82 M843.12 M755.78 M703.03 M755.46 M903.32 M756.95 M925.68 M
Consensus Estimate 732.65 M748.41 M687.84 M705.27 M754.46 M765.76 M685.02 M815.10 M781.96 M876.57 M815.91 M778.13 M820.69 M947.51 M819.31 M964.96 M
Analyst Estimates

Amneal Pharmaceuticals, Inc. Earnings Per Share (EPS) Estimates

Periods 22
Next Period Q3 26
Consensus 0.21

Analysts expect Amneal Pharmaceuticals, Inc. to report earnings per share of 0.21 for Q3 26, against a range of 0.19 to 0.23. The most recent reported quarter, Q2 26, came in at 0.30, a 30.4% beat against the 0.23 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 0.160.120.210.250.170.210.270.30--------
High Estimate 0.140.170.150.180.150.200.170.250.230.230.280.300.240.290.380.46
Low Estimate 0.120.150.130.160.130.180.150.210.190.210.260.280.200.270.340.38
Consensus Estimate 0.130.160.140.170.140.190.160.230.210.220.270.290.220.280.360.42